GMAB – Genmab A/S

Float Short %

0.63

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

-0.14

EPS Last/This Y

-0.02

EPS This/Next Y

0.07

Price

27.81

Target Price

31.61

Analyst Recom

1.78

Performance Q

20.49

Relative Volume

1.08

Beta

0.95

Ticker: GMAB

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	GMAB	23.3	0.36	0.08	3569
2025-08-18	GMAB	23.42	0.25	0.67	1453
2025-08-19	GMAB	23.82	0.27	0.01	1485
2025-08-20	GMAB	24.08	0.21	0.53	1814
2025-08-21	GMAB	24.42	0.22	0.08	1825
2025-08-22	GMAB	24.65	0.26	0.26	1720
2025-08-25	GMAB	24.3	0.25	0.75	1746
2025-08-26	GMAB	24.52	0.26	0.00	1768
2025-08-27	GMAB	24.78	0.26	0.14	1771
2025-08-28	GMAB	25.1	0.26	0.24	1772
2025-08-29	GMAB	24.86	0.26	1.67	1783
2025-09-02	GMAB	25.9	0.25	0.14	1780
2025-09-03	GMAB	27.07	0.25	0.33	1832
2025-09-04	GMAB	27.39	0.26	0.06	1980
2025-09-05	GMAB	27.55	0.27	0.53	1975
2025-09-08	GMAB	27.55	0.30	0.75	1957
2025-09-09	GMAB	27.84	0.30	0.21	1958
2025-09-10	GMAB	27.72	0.34	0.07	2014
2025-09-11	GMAB	28.63	0.34	0.06	2019
2025-09-12	GMAB	27.81	0.34	0.06	2003
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	GMAB	23.31	53.2	-689.1	1.75
2025-08-18	GMAB	23.42	53.2	-707.3	1.75
2025-08-19	GMAB	23.82	53.2	-698.9	1.75
2025-08-20	GMAB	24.07	53.2	-693.7	1.75
2025-08-21	GMAB	24.42	53.2	-696.7	1.73
2025-08-22	GMAB	24.65	53.2	-705.8	1.73
2025-08-25	GMAB	24.30	53.2	-715.4	1.73
2025-08-26	GMAB	24.54	53.2	-710.6	1.73
2025-08-27	GMAB	24.78	53.2	-702.5	1.73
2025-08-28	GMAB	25.11	53.2	-699.4	1.73
2025-08-29	GMAB	24.86	53.2	-719.6	1.73
2025-09-02	GMAB	25.90	53.2	-683.1	1.73
2025-09-03	GMAB	27.09	53.2	-500.6	1.73
2025-09-04	GMAB	27.39	53.2	-537.5	1.73
2025-09-05	GMAB	27.54	53.2	174.4	1.73
2025-09-08	GMAB	27.54	58.3	168.4	1.68
2025-09-09	GMAB	27.85	58.3	200.6	1.68
2025-09-10	GMAB	27.72	58.3	168.0	1.68
2025-09-11	GMAB	28.61	58.3	219.0	1.68
2025-09-12	GMAB	27.81	58.3	107.1	1.68
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	GMAB	0	-0.45	0.58
2025-08-18	GMAB	0	-0.41	0
2025-08-19	GMAB	0	-0.41	0.58
2025-08-20	GMAB	0	-0.41	0.58
2025-08-21	GMAB	0	-0.41	0.58
2025-08-22	GMAB	0	-0.41	0.58
2025-08-25	GMAB	0	-0.15	0.58
2025-08-26	GMAB	0	-0.15	0.58
2025-08-27	GMAB	0	-0.15	0.56
2025-08-28	GMAB	0	-0.15	0.56
2025-08-29	GMAB	0	-0.15	0.56
2025-09-02	GMAB	0	-0.18	0.56
2025-09-03	GMAB	0	-0.18	0.56
2025-09-04	GMAB	0	-0.18	0.56
2025-09-05	GMAB	0	-0.18	0.56
2025-09-08	GMAB	0	-0.21	0.56
2025-09-09	GMAB	0	-0.21	0.56
2025-09-10	GMAB	0	-0.21	0.56
2025-09-11	GMAB	0	-0.21	0.63
2025-09-12	GMAB	0	-0.21	0.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.54

Avg. EPS Est. Current Quarter

0.45

Avg. EPS Est. Next Quarter

0.4

Insider Transactions

Institutional Transactions

-0.21

Beta

0.95

Average Sales Estimate Current Quarter

6208

Average Sales Estimate Next Quarter

6510

Fair Value

Quality Score

100

Growth Score

Sentiment Score

Actual DrawDown %

43.3

Max Drawdown 5-Year %

-63.1

Target Price

31.61

P/E

13.89

Forward P/E

14.22

PEG

1.15

P/S

5.05

P/B

3.23

P/Free Cash Flow

17.02

EPS

Average EPS Est. Cur. Y

1.68

EPS Next Y. (Est.)

1.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.52

Relative Volume

1.08

Return on Equity vs Sector %

-1.7

Return on Equity vs Industry %

11.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.34

EBIT Estimation

107.1

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2639

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Float Short %

0.77

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

5.06

EPS Last/This Y

EPS This/Next Y

0.51

Price

54.92

Target Price

72.15

Analyst Recom

2.16

Performance Q

-32.3

Relative Volume

0.65

Beta

0.69

Ticker: NVO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	NVO	52.39	0.82	0.20	1255522
2025-08-18	NVO	53.81	0.84	0.30	1093936
2025-08-19	NVO	54.76	0.80	0.38	1140084
2025-08-20	NVO	54.32	0.81	0.46	1152990
2025-08-21	NVO	55.46	0.81	0.84	1161573
2025-08-22	NVO	56.97	0.80	0.33	1175061
2025-08-25	NVO	56.32	0.81	0.28	1137587
2025-08-26	NVO	55.34	0.80	0.44	1164728
2025-08-27	NVO	56.36	0.80	0.46	1183521
2025-08-28	NVO	56.09	0.81	0.52	1192043
2025-08-29	NVO	56.47	0.80	0.44	1193588
2025-09-02	NVO	56.36	0.80	0.39	1137614
2025-09-03	NVO	56.72	0.80	0.68	1149107
2025-09-04	NVO	56.12	0.81	0.65	1163862
2025-09-05	NVO	55.22	0.80	0.54	1177748
2025-09-08	NVO	54.27	0.80	0.51	1152827
2025-09-09	NVO	54.15	0.80	0.52	1165607
2025-09-10	NVO	54.38	0.80	0.45	1183664
2025-09-11	NVO	54.29	0.80	0.78	1196762
2025-09-12	NVO	54.93	0.81	0.72	1211637
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	NVO	52.40	-3.7	-2488.1	24.52
2025-08-18	NVO	53.77	-3.7	-1994.9	24.52
2025-08-19	NVO	54.78	-3.9	-2905.3	24.84
2025-08-20	NVO	54.31	-3.9	-1683.8	24.84
2025-08-21	NVO	55.46	-3.7	-1094.6	24.84
2025-08-22	NVO	56.98	-3.7	-2040.8	24.84
2025-08-25	NVO	56.32	-3.7	-2640.0	24.84
2025-08-26	NVO	55.34	-3.7	-3166.2	24.84
2025-08-27	NVO	56.44	-3.7	-1864.4	24.84
2025-08-28	NVO	56.11	-3.7	-2383.4	24.84
2025-08-29	NVO	56.51	-3.7	-2121.6	24.84
2025-09-02	NVO	56.37	-3.8	-2018.0	24.83
2025-09-03	NVO	56.76	-3.8	-389.7	24.83
2025-09-04	NVO	56.14	-3.8	-770.0	24.83
2025-09-05	NVO	55.23	-3.7	-753.6	24.84
2025-09-08	NVO	54.28	-3.7	-490.8	24.84
2025-09-09	NVO	54.30	-3.7	-292.8	24.84
2025-09-10	NVO	54.38	-3.7	270.0	24.84
2025-09-11	NVO	54.30	-3.7	-553.7	24.84
2025-09-12	NVO	54.92	-3.7	-281.7	24.84
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	NVO	0	-5.72	0.62
2025-08-18	NVO	0	-5.78	0.62
2025-08-19	NVO	0	-5.78	0.62
2025-08-20	NVO	0	-5.78	0.62
2025-08-21	NVO	0	-5.78	0.62
2025-08-22	NVO	0	-5.78	0.62
2025-08-25	NVO	0.00	-3.92	0.62
2025-08-26	NVO	0	-3.92	0.62
2025-08-27	NVO	0	-3.92	0.62
2025-08-28	NVO	0	-3.92	0.62
2025-08-29	NVO	0	-3.92	0.62
2025-09-02	NVO	0	-4.58	0.62
2025-09-03	NVO	0	-4.58	0.62
2025-09-04	NVO	0	-4.58	0.62
2025-09-05	NVO	0	-4.58	0.62
2025-09-08	NVO	0	-5.12	0.62
2025-09-09	NVO	0	-5.12	0.62
2025-09-10	NVO	0	-5.12	0.62
2025-09-11	NVO	0	-5.12	0.77
2025-09-12	NVO	0	-5.12	0.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.97

Avg. EPS Est. Current Quarter

5.89

Avg. EPS Est. Next Quarter

6.03

Insider Transactions

Institutional Transactions

-5.12

Beta

0.69

Average Sales Estimate Current Quarter

77663

Average Sales Estimate Next Quarter

84062

Fair Value

62.06

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

62.9

Max Drawdown 5-Year %

-68.5

Target Price

72.15

P/E

15.12

Forward P/E

13.1

PEG

1.16

P/S

4.06

P/B

9.22

P/Free Cash Flow

19.46

EPS

3.63

Average EPS Est. Cur. Y

24.84

EPS Next Y. (Est.)

25.34

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.6

Relative Volume

0.65

Return on Equity vs Sector %

41.2

Return on Equity vs Industry %

32.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-281.7

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78387

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Float Short %

4.46

Margin Of Safety %

Put/Call OI Ratio

0.98

EPS Next Q Diff

0.9

EPS Last/This Y

5.09

EPS This/Next Y

5.34

Price

195.57

Target Price

247.45

Analyst Recom

Performance Q

14.43

Relative Volume

0.49

Beta

0.41

Ticker: ASND

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	ASND	198.34	0.96	0.39	16333
2025-08-18	ASND	194.01	1.11	0.01	8481
2025-08-19	ASND	194.3	1.34	2.20	7795
2025-08-20	ASND	191.92	1.34	1.11	7811
2025-08-21	ASND	193.8	1.35	0.15	7864
2025-08-22	ASND	194.13	1.36	0.06	7850
2025-08-25	ASND	190.07	1.36	3.36	7855
2025-08-26	ASND	196.66	1.37	1.83	7944
2025-08-27	ASND	193.04	1.36	0.01	8035
2025-08-28	ASND	194.11	1.12	0.14	8799
2025-08-29	ASND	194.1	1.11	4.38	8809
2025-09-02	ASND	198.82	1.11	0.24	8794
2025-09-03	ASND	199.56	1.10	0.03	8859
2025-09-04	ASND	198.26	0.91	1.99	9783
2025-09-05	ASND	205.91	0.93	0.44	9936
2025-09-08	ASND	205.52	0.93	0.35	9918
2025-09-09	ASND	202.84	0.94	0.46	9924
2025-09-10	ASND	198.73	0.97	0.33	10164
2025-09-11	ASND	197.47	0.98	0.05	10149
2025-09-12	ASND	195.52	0.98	0.64	10141
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	ASND	198.20	82.7	54.3	-2.39
2025-08-18	ASND	194.32	82.7	61.9	-2.39
2025-08-19	ASND	194.62	82.7	58.5	-2.39
2025-08-20	ASND	192.71	84.3	60.3	-2.46
2025-08-21	ASND	192.96	84.3	58.7	-2.46
2025-08-22	ASND	194.30	84.3	57.7	-2.46
2025-08-25	ASND	190.03	84.3	62.2	-2.46
2025-08-26	ASND	196.66	84.3	54.2	-2.46
2025-08-27	ASND	193.02	84.3	61.8	-2.46
2025-08-28	ASND	193.90	84.3	58.4	-2.46
2025-08-29	ASND	194.14	84.3	58.9	-2.46
2025-09-02	ASND	199.27	84.3	55.2	-2.46
2025-09-03	ASND	199.91	84.3	423.7	-2.46
2025-09-04	ASND	198.09	84.3	420.9	-2.46
2025-09-05	ASND	205.91	84.3	429.3	-2.46
2025-09-08	ASND	205.22	84.3	420.6	-2.46
2025-09-09	ASND	202.82	83.5	418.9	-2.51
2025-09-10	ASND	198.46	83.5	416.9	-2.51
2025-09-11	ASND	197.67	83.5	420.6	-2.51
2025-09-12	ASND	195.57	83.5	419.2	-2.51
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	ASND	0.00	1.26	4.58
2025-08-18	ASND	0.00	0.40	4.58
2025-08-19	ASND	0.00	0.40	4.58
2025-08-20	ASND	0.00	0.40	4.58
2025-08-21	ASND	0.00	0.40	4.58
2025-08-22	ASND	0.00	0.40	4.58
2025-08-25	ASND	0.00	-4.90	4.58
2025-08-26	ASND	0.00	-4.90	4.58
2025-08-27	ASND	0.00	-4.90	4.14
2025-08-28	ASND	0.00	-4.90	4.14
2025-08-29	ASND	0.00	-4.90	4.14
2025-09-02	ASND	0.00	-5.03	4.14
2025-09-03	ASND	0.00	-5.03	4.14
2025-09-04	ASND	0.00	-5.03	4.14
2025-09-05	ASND	0.00	-5.03	4.14
2025-09-08	ASND	0.00	-5.02	4.14
2025-09-09	ASND	0.00	-5.02	4.14
2025-09-10	ASND	0.00	-5.02	4.14
2025-09-11	ASND	0.00	-5.02	4.46
2025-09-12	ASND	0.00	-5.02	4.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.93

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

Institutional Transactions

-5.02

Beta

0.41

Average Sales Estimate Current Quarter

209

Average Sales Estimate Next Quarter

261

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-61.7

Target Price

247.45

P/E

Forward P/E

50.1

PEG

P/S

22.15

P/B

P/Free Cash Flow

EPS

-4.97

Average EPS Est. Cur. Y

-2.51

EPS Next Y. (Est.)

2.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-54.94

Relative Volume

0.49

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

1.21

EBIT Estimation

419.2

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y